Articles from Masimo Corporation

Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 28, 2024 and provided estimates for its full-year 2025 guidance.

Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 28, 2024.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today is sharing a summary of the core issues to consider in this contest for control of the Masimo Board and urging stockholders to vote “FOR” only Masimo’s Director Nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today issued a statement following two rulings by the U.S. District Court for the Central District of California (“the Court”): one that finds Politan Capital Management LP (“Politan”) and Quentin Koffey are in contempt of court in connection with their September 12, 2024 violation of a court order, and another that finds Politan made false and misleading statements to stockholders.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today announced that leading proxy advisory firm Egan-Jones has recommended that stockholders vote on the updated GOLD proxy card “FOR” ONLY Masimo’s director nominees – Joe Kiani and Christopher Chavez – in connection with its September 19, 2024 Annual Meeting of Stockholders (the “Annual Meeting”).

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today set the record straight in response to Politan Capital Management LP (“Politan”) and Quentin Koffey’s preemptive press release regarding an order from the U.S. District Court for the Central District of California that is still under seal.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 19, 2024, underscoring the importance of stockholders’ vote in determining the future of the Company and value of their investment.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 19, 2024, highlighting critical details about Politan and Quentin Koffey’s plan to take control of Masimo and failure to act in the best interests of all Masimo stockholders.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 19, 2024, highlighting the Company’s commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company’s Board of Directors.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today announced that it has filed revised definitive proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 19, 2024. Stockholders of record as of the close of business on August 12, 2024 are entitled to vote at the Annual Meeting.

Masimo Corporation (Nasdaq: MASI) today announced its financial results for the second quarter ended June 29, 2024.

Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that it has commenced litigation against Politan Capital Management LP (“Politan”) in federal court in California seeking to require Politan to correct material misstatements and omissions in Politan’s proxy materials. The complaint alleges, among other things, that Quentin Koffey has assisted plaintiff’s counsel in litigation against Masimo. Masimo has also set a new date for its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) and a new record date to ensure that the vote of the Company’s stockholders is fair and fully informed.

To ensure that Politan lies repeated over and over are not taken as fact, Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI) sets forth below facts in response to what we believe are some of Politan’s and Quentin Koffey’s most egregious and continuing misrepresentations.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI) today highlighted the actions taken by Politan and Quentin Koffey since Masimo’s 2023 Annual Meeting of Stockholders that directly contradict their purported commitment to good governance.

Masimo Corporation (Nasdaq: MASI) today announced preliminary revenue and select financial results for the second quarter ended June 29, 2024.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI) today issued the following statement to address what Masimo strongly believes is Politan’s campaign of deception and distraction to deflect attention from its own failures and its nominees’ shortcomings.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI) today issued a letter to stockholders in connection with the Company’s 2024 Annual Meeting of Stockholders. The letter highlights the fierce independence and deep medtech experience of nominee Christopher Chavez and contrasts it to Politan’s handpicked and paid nominees. Masimo believes that ceding control of Masimo to Politan by electing its nominees would jeopardize the value of your investment in Masimo. The Board encourages stockholders to vote FOR Masimo’s highly qualified director nominees, Joe Kiani and Christopher Chavez.

Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on July 25, 2024. The presentation lays out in detail:

Members of the Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI) Board of Directors today issued a letter to stockholders in connection with its definitive proxy materials filed on June 17, 2024, and the Company’s Annual Meeting of Stockholders to be held on July 25, 2024. The letter highlights what in our view are the significant risks to the value of Masimo if control of the Board is ceded to Politan Capital Management (“Politan”), which we believe wants to eliminate some of the key people and practices that have fueled Masimo’s long-term innovation and growth and supported its premium valuation multiple. The letter also details the Company’s excellent positioning to continue to drive above-market organic growth and meaningful margin expansion, while highlighting the expertise and experience of Masimo’s highly qualified director nominees. To protect stockholders’ investment and the Company’s future, the Board strongly encourages stockholders to vote FOR Masimo’s exceptional director nominees, Joe Kiani and Christopher Chavez.

Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 30, 2024.

Masimo (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today announced that its Board of Directors has authorized management to evaluate a proposed separation of its consumer business. The Board and management will evaluate the proposed structure of the separation. Masimo expects that the separation will include its consumer audio and consumer health products, including the Stork baby monitor and the Freedom smart watch and band. Masimo will retain its professional healthcare and telehealth products. Masimo expects that this will improve the profitability of the healthcare business. Joe Kiani is expected to remain Chairman and CEO of Masimo and to be named Chairman of the newly created company. Masimo will seek to complete the separation as soon as feasible, subject to completion of due diligence, completion of definitive agreements, submission and clearance of filings with the Securities and Exchange Commission and the receipt of other applicable regulatory approvals.

Masimo (NASDAQMASI) today announced that its management will participate in the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5, 2024 at 3:25 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 30, 2023.

Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance.

Masimo (NASDAQMASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors. Mr. Classon is an experienced medical technology executive and board member. From October 2002 until his retirement in July 2004, he was Chairman of the Executive Committee of Bayer HealthCare AG. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President of Bayer Diagnostics from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation.

Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter of 2023, ended September 30, 2023.

Masimo Corporation (Nasdaq: MASI) today announced its financial results for the second quarter of 2023, ended July 1, 2023.

Masimo Corporation (Nasdaq: MASI) today announced preliminary revenue results for the second quarter ended July 1, 2023.

The Board of Directors of Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today issued a letter to stockholders in connection with the Company’s Annual Meeting of Stockholders to be held on June 26, 2023. To protect stockholders’ investment and to ensure Masimo continues to innovate breakthrough solutions to help improve lives, improve patient outcomes and reduce cost of care, and take noninvasive monitoring to new sites and applications, the Board encourages stockholders to vote FOR Masimo’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Your vote on the WHITE proxy card helps prevent Politan Capital Management (“Politan”) and its nominee Quentin Koffey from endangering Masimo’s current position and the future it is trying to bring about.

The Board of Directors of Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today issued a letter to stockholders in connection with the Company’s Annual Meeting of Stockholders to be held on June 26, 2023. The letter outlines the importance of Masimo’s mission-driven innovation to its financial success and how Politan Capital Management (“Politan”) nominee Quentin Koffey’s ill-informed plans to meddle in Masimo’s R&D strategy endanger the Company’s future.

Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today announced that Joe Kiani, founder, Chairman and Chief Executive Officer of Masimo, unconditionally, irrevocably and permanently waived his right to assert that a Change in Control has occurred pursuant to Section 9(iii) of his employment agreement unless there occurs a change in the Company’s Board in which the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding the change cease for any reason to constitute one-half or more of the directors then in office. The full text of the waiver has been filed with the U.S. Securities and Exchange Commission. Mr. Kiani previously waived his rights to assert that a Change in Control has occurred as a result of the election of stockholder-nominated directors at the 2023 annual meeting of stockholders, and that the appointment of any lead independent director of the Board constitutes Good Reason under his employment agreement.

On June 2, 2023, Masimo Corporation (“Masimo”) issued the following press release in connection with Masimo’s 2023 Annual Meeting of Stockholders, which corrects Masimo’s press release issued earlier on June 2, 2023 (the “Prior Release”).

Masimo Corporation (Nasdaq: MASI) today announced changes to its Board of Directors and governance policies, the result of an ongoing board refreshment and governance review process informed by regular engagement with stockholders.

Masimo Corporation (Nasdaq: MASI) (“Masimo” or the “Company”) will host its Investor Day today. At the event, Masimo’s management team will provide an update on the Company’s business and strategic plans, including deep dives into its segments, sustainability and responsibility efforts and financial outlook for 2023 and beyond. Members of the leadership team will outline Masimo’s growth opportunities and strategies across consumer health, consumer audio and professional healthcare.

Masimo Corporation (Nasdaq: MASI) today announced certain preliminary financial results for the first quarter ending April 2, 2022 and reaffirmed its full-year 2022 revenue guidance.

Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial and operational results for the full-year ended January 1, 2022 and provided estimates for its full-year 2022 financial guidance.

Masimo (NASDAQMASI) today announced that its management is scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 4:15 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.